KL0011034 clinical trials
How each study uses KL0011034 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the KL0011034 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- KL0011034 injection
- 6
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 2
Hunan Kelun Pharmaceutical Co., Ltd. (4) · The Third Xiangya Hospital of Central South University (2)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test KL0011034.
- Nov 2026A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of KL0011034 Injection Administered by Continuous Infusion in Healthy Adult SubjectsPhase 1 · Hunan Kelun Pharmaceutical Co., Ltd.
- Nov 2026A Study to Evaluate the PK/PD and Safety of KL0011034 Injection in Healthy Non-Elderly and Elderly Trial ParticipantsPhase 1 · Hunan Kelun Pharmaceutical Co., Ltd.
- Jul 2027A Study to Evaluate the Drug-Drug Interaction Between KL0011034 Injection and Alfentanil Hydrochloride Injection in Participants With Moderate-to-Severe Non-Cancer Chronic PainPhase 1 · The Third Xiangya Hospital of Central South University
- Sep 2027Safety, Pharmacokinetics, and Pharmacodynamics of Continuous KL0011034 Infusion in Healthy Chinese AdultsPhase 1 · The Third Xiangya Hospital of Central South University
Studies
Open first, then newest update. How each study uses KL0011034 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study to Evaluate the PK/PD and Safety of KL0011034 Injection in Healthy Non-Elderly and Elderly Trial ParticipantsNot yet recruitingPhase 1Hunan Kelun Pharmaceutical Co., Ltd.NCT07913048Written as KL0011034 injection
- Safety, Pharmacokinetics, and Pharmacodynamics of Continuous KL0011034 Infusion in Healthy Chinese AdultsNot yet recruitingPhase 1The Third Xiangya Hospital of Central South UniversityNCT07841626Written as KL0011034 Injection
- A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of KL0011034 Injection Administered by Continuous Infusion in Healthy Adult SubjectsNot yet recruitingPhase 1Hunan Kelun Pharmaceutical Co., Ltd.NCT07828470Written as KL0011034 injection
- A Study to Evaluate the Drug-Drug Interaction Between KL0011034 Injection and Alfentanil Hydrochloride Injection in Participants With Moderate-to-Severe Non-Cancer Chronic PainNot yet recruitingPhase 1The Third Xiangya Hospital of Central South UniversityNCT07751094Written as KL0011034 injection
- A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KL0011034 Injection in Healthy VolunteersRecruitingPhase 1Hunan Kelun Pharmaceutical Co., Ltd.NCT07474545Written as KL0011034 injection
- A Study Evaluating the Drug-Drug Interaction Between KL0011034 Injection and Alfentanil Hydrochloride InjectionCompletedPhase 1Hunan Kelun Pharmaceutical Co., Ltd.NCT07710560Written as KL0011034 injection
What changed recently
From the registry's own updates since Oct 18, 2026.